vs

Side-by-side financial comparison of ENERPAC TOOL GROUP CORP (EPAC) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.

ENERPAC TOOL GROUP CORP is the larger business by last-quarter revenue ($144.2M vs $123.8M, roughly 1.2× NATURES SUNSHINE PRODUCTS INC). ENERPAC TOOL GROUP CORP runs the higher net margin — 13.3% vs 3.3%, a 9.9% gap on every dollar of revenue. On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs -0.7%). ENERPAC TOOL GROUP CORP produced more free cash flow last quarter ($13.3M vs $7.6M). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs 2.1%).

Enerpac Tool Group Corp., formerly Actuant Corporation, was founded in 1910 and is headquartered in Menomonee Falls, Wisconsin. Enerpac Tool Group common stock trades on the NYSE under the symbol EPAC.

Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.

EPAC vs NATR — Head-to-Head

Bigger by revenue
EPAC
EPAC
1.2× larger
EPAC
$144.2M
$123.8M
NATR
Growing faster (revenue YoY)
NATR
NATR
+5.4% gap
NATR
4.7%
-0.7%
EPAC
Higher net margin
EPAC
EPAC
9.9% more per $
EPAC
13.3%
3.3%
NATR
More free cash flow
EPAC
EPAC
$5.7M more FCF
EPAC
$13.3M
$7.6M
NATR
Faster 2-yr revenue CAGR
NATR
NATR
Annualised
NATR
5.6%
2.1%
EPAC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
EPAC
EPAC
NATR
NATR
Revenue
$144.2M
$123.8M
Net Profit
$19.1M
$4.1M
Gross Margin
50.7%
72.5%
Operating Margin
19.8%
4.3%
Net Margin
13.3%
3.3%
Revenue YoY
-0.7%
4.7%
Net Profit YoY
-11.9%
1379.4%
EPS (diluted)
$0.36
$0.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EPAC
EPAC
NATR
NATR
Q4 25
$144.2M
$123.8M
Q3 25
$167.5M
$128.3M
Q2 25
$158.7M
$114.8M
Q1 25
$145.5M
$113.2M
Q4 24
$145.2M
$118.2M
Q3 24
$158.7M
$114.6M
Q2 24
$150.4M
$110.6M
Q1 24
$138.4M
$111.0M
Net Profit
EPAC
EPAC
NATR
NATR
Q4 25
$19.1M
$4.1M
Q3 25
$28.1M
$5.3M
Q2 25
$22.0M
$5.3M
Q1 25
$20.9M
$4.7M
Q4 24
$21.7M
$-321.0K
Q3 24
$24.4M
$4.3M
Q2 24
$25.8M
$1.3M
Q1 24
$17.8M
$2.3M
Gross Margin
EPAC
EPAC
NATR
NATR
Q4 25
50.7%
72.5%
Q3 25
50.1%
73.3%
Q2 25
50.4%
71.7%
Q1 25
50.5%
72.1%
Q4 24
51.4%
72.0%
Q3 24
48.8%
71.3%
Q2 24
51.8%
71.4%
Q1 24
51.6%
71.2%
Operating Margin
EPAC
EPAC
NATR
NATR
Q4 25
19.8%
4.3%
Q3 25
23.8%
7.0%
Q2 25
20.0%
3.7%
Q1 25
21.2%
5.4%
Q4 24
21.4%
3.8%
Q3 24
18.9%
4.6%
Q2 24
22.2%
5.1%
Q1 24
21.3%
4.2%
Net Margin
EPAC
EPAC
NATR
NATR
Q4 25
13.3%
3.3%
Q3 25
16.8%
4.2%
Q2 25
13.9%
4.6%
Q1 25
14.4%
4.2%
Q4 24
15.0%
-0.3%
Q3 24
15.4%
3.8%
Q2 24
17.1%
1.2%
Q1 24
12.9%
2.1%
EPS (diluted)
EPAC
EPAC
NATR
NATR
Q4 25
$0.36
$0.23
Q3 25
$0.51
$0.30
Q2 25
$0.41
$0.28
Q1 25
$0.38
$0.25
Q4 24
$0.40
$-0.02
Q3 24
$0.44
$0.23
Q2 24
$0.47
$0.07
Q1 24
$0.33
$0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EPAC
EPAC
NATR
NATR
Cash + ST InvestmentsLiquidity on hand
$139.0M
$93.9M
Total DebtLower is stronger
$188.8M
Stockholders' EquityBook value
$431.1M
$161.6M
Total Assets
$818.1M
$261.1M
Debt / EquityLower = less leverage
0.44×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EPAC
EPAC
NATR
NATR
Q4 25
$139.0M
$93.9M
Q3 25
$151.6M
$95.6M
Q2 25
$140.5M
$81.3M
Q1 25
$119.5M
$86.5M
Q4 24
$130.7M
$84.7M
Q3 24
$167.1M
$78.7M
Q2 24
$132.4M
$68.7M
Q1 24
$153.7M
$77.8M
Total Debt
EPAC
EPAC
NATR
NATR
Q4 25
$188.8M
Q3 25
$190.0M
Q2 25
$191.3M
Q1 25
$192.5M
Q4 24
$193.8M
Q3 24
$195.0M
Q2 24
$196.3M
Q1 24
$245.5M
$2.1M
Stockholders' Equity
EPAC
EPAC
NATR
NATR
Q4 25
$431.1M
$161.6M
Q3 25
$433.7M
$166.7M
Q2 25
$438.2M
$163.7M
Q1 25
$406.0M
$167.1M
Q4 24
$398.0M
$161.0M
Q3 24
$392.0M
$162.6M
Q2 24
$365.8M
$156.4M
Q1 24
$336.9M
$159.7M
Total Assets
EPAC
EPAC
NATR
NATR
Q4 25
$818.1M
$261.1M
Q3 25
$827.9M
$264.8M
Q2 25
$828.1M
$254.9M
Q1 25
$776.6M
$252.7M
Q4 24
$775.4M
$240.9M
Q3 24
$777.3M
$245.3M
Q2 24
$749.5M
$235.8M
Q1 24
$769.3M
$247.3M
Debt / Equity
EPAC
EPAC
NATR
NATR
Q4 25
0.44×
Q3 25
0.44×
Q2 25
0.44×
Q1 25
0.47×
Q4 24
0.49×
Q3 24
0.50×
Q2 24
0.54×
Q1 24
0.73×
0.01×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EPAC
EPAC
NATR
NATR
Operating Cash FlowLast quarter
$16.0M
$9.9M
Free Cash FlowOCF − Capex
$13.3M
$7.6M
FCF MarginFCF / Revenue
9.2%
6.1%
Capex IntensityCapex / Revenue
1.9%
1.9%
Cash ConversionOCF / Net Profit
0.84×
2.41×
TTM Free Cash FlowTrailing 4 quarters
$102.5M
$28.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EPAC
EPAC
NATR
NATR
Q4 25
$16.0M
$9.9M
Q3 25
$55.3M
$18.5M
Q2 25
$39.9M
$4.3M
Q1 25
$7.5M
$2.6M
Q4 24
$8.6M
$12.2M
Q3 24
$44.4M
$9.6M
Q2 24
$30.3M
$1.3M
Q1 24
$13.3M
$2.2M
Free Cash Flow
EPAC
EPAC
NATR
NATR
Q4 25
$13.3M
$7.6M
Q3 25
$52.3M
$16.8M
Q2 25
$35.1M
$3.0M
Q1 25
$1.8M
$1.5M
Q4 24
$2.8M
$10.0M
Q3 24
$37.9M
$7.9M
Q2 24
$28.5M
$-2.0M
Q1 24
$11.7M
$-1.5M
FCF Margin
EPAC
EPAC
NATR
NATR
Q4 25
9.2%
6.1%
Q3 25
31.2%
13.1%
Q2 25
22.1%
2.6%
Q1 25
1.2%
1.3%
Q4 24
1.9%
8.5%
Q3 24
23.9%
6.9%
Q2 24
18.9%
-1.9%
Q1 24
8.5%
-1.4%
Capex Intensity
EPAC
EPAC
NATR
NATR
Q4 25
1.9%
1.9%
Q3 25
1.8%
1.3%
Q2 25
3.1%
1.2%
Q1 25
3.9%
1.0%
Q4 24
4.0%
1.9%
Q3 24
4.1%
1.5%
Q2 24
1.2%
3.0%
Q1 24
1.1%
3.3%
Cash Conversion
EPAC
EPAC
NATR
NATR
Q4 25
0.84×
2.41×
Q3 25
1.97×
3.46×
Q2 25
1.81×
0.81×
Q1 25
0.36×
0.55×
Q4 24
0.40×
Q3 24
1.82×
2.21×
Q2 24
1.18×
0.97×
Q1 24
0.75×
0.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EPAC
EPAC

Transferred At Point In Time$126.0M87%
Other$12.1M8%
Other Operating Segment$6.1M4%

NATR
NATR

Other$68.1M55%
General Health Products$20.2M16%
Digestive Products$13.8M11%
Cardiovascular Products$12.1M10%
Personal Care Products$4.4M4%
Immunity Products$3.1M3%
Weight Management Products$2.1M2%

Related Comparisons